STOCK TITAN

Vanguard realigns reporting; subsidiaries to report separately (Illumina, ILMN)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Illumina Inc: The Vanguard Group filed an amendment to its Schedule 13G disclosing zero shares of Illumina common stock beneficially owned following an internal realignment effective January 12, 2026. The filing states Vanguard subsidiaries that formerly reported with The Vanguard Group will now report separately in reliance on SEC Release No. 34-39538.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports no beneficial ownership after organizational realignment.

The amendment states Amount beneficially owned: 0 and Percent of class: 0%, reflecting a reporting change where subsidiaries will report separately in reliance on SEC Release No. 34-39538.

Cash-flow treatment and trading intentions are not stated; subsequent filings from Vanguard subsidiaries may show any continuing positions.

Change appears administrative under SEC guidance, not an economic disposition.

The filing cites the January 12, 2026 internal realignment and SEC Release No. 34-39538 as the basis for disaggregation of beneficial ownership reporting. The statement indicates prior strategies continue but reporting is separated.

Material investor impact depends on whether subsidiaries later report holdings; timing and amounts are not disclosed here.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

What did Vanguard report for ILMN in this Schedule 13G/A?

Vanguard reported zero shares beneficially owned and 0% of Illumina common stock. The amendment reflects reporting changes after an internal realignment effective January 12, 2026 under SEC Release No. 34-39538.

Does this filing mean Vanguard sold Illumina (ILMN) shares?

No. The filing attributes the change to an internal realignment and separate reporting by subsidiaries, citing SEC Release No. 34-39538. It states the subsidiaries pursue the same strategies; it does not state sales or cash-flow details.

When did Vanguard's internal realignment occur according to the filing?

The filing states the internal realignment occurred on January 12, 2026. It explains that certain subsidiaries will report beneficial ownership separately in reliance on SEC Release No. 34-39538.

Who signed the Schedule 13G/A amendment for Vanguard on ILMN?

The amendment was signed by Ashley Grim, listed as Head of Global Fund Administration, with the signature date shown as 03/27/2026 on the filing.

Will this filing show any subsidiary holdings of ILMN?

This amendment reports 0 beneficial shares for The Vanguard Group itself. It states subsidiaries will report separately; any subsidiary holdings would appear in separate filings by those entities, not in this amendment.
Illumina Inc

NASDAQ:ILMN

View ILMN Stock Overview

ILMN Rankings

ILMN Latest News

ILMN Latest SEC Filings

ILMN Stock Data

19.02B
152.52M
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States
SAN DIEGO